
Immunological changes in the ascites of cancer patients after intraperitoneal administration of the bispecific antibody catumaxomab (anti-EpCAM × anti-CD3)
Keywords: Immunomodulatory activity; Catumaxomab; Malignant ascites; Bispecific monoclonal antibody